No Data
Vaxart, Inc.'s (NASDAQ:VXRT) 39% Share Price Surge Not Quite Adding Up
B.Riley Financial Maintains Vaxart(VXRT.US) With Buy Rating, Maintains Target Price $2.5
Vaxart's Promising Vaccine Pipeline: Leading in Mucosal Immunity With Government Support and Competitive Advantages
Oppenheimer Starts Vaxart at Outperform, Cites Oral Vaccine Focus
Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside
Express News | Vaxart Shares Are Trading Higher After Oppenheimer Initiated Coverage on the Stock With an Outperform Rating and Announced a $4 Price Target